Class I recalls involve a reasonable probability of serious adverse health consequences or death; Class II involves temporary or medically reversible harm; Class III is unlikely to cause adverse health consequences. FDA assigns the class after a health hazard evaluation, considering things like the likelihood of harm, the severity and the population at risk. Class I recalls get the most attention: FDA typically issues public notices and expects the firm to check effectiveness at the user level. Classification affects how widely the firm must notify customers and how FDA checks that the recall is complete.

Why it matters

Classification determines public notification expectations and effectiveness-check rigor. The Recall Strategy and Health Hazard Evaluation drive the classification decision.

Common pitfalls

•Misinterpreting a Class II recall as less critical, potentially delaying appropriate corrective actions.
•Failing to conduct a thorough Health Hazard Evaluation, which can lead to an incorrect recall classification.
•Underestimating the resources required for a Class I recall, impacting the speed and effectiveness of product removal.
•Not understanding that even Class III recalls require proper documentation and communication with the FDA.
•Assuming that a recall classification is permanent and cannot be re-evaluated if new information arises.

Sources

21 CFR Part 7, Recalls · eCFR
FDA Recalls - Medical Devices · FDA
EUDAMED Public Site · European Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.